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Abstract 1 
Background - Timothy syndrome (TS) is an extremely rare multisystem disorder 2 
characterized by marked QT prolongation, syndactyly, seizures, behavioral 3 
abnormalities, immunodeficiency and hypoglycemia. There is a propensity to 4 
develop malignant arrhythmias at a young age, with many patients requiring 5 
defibrillator implantation.  6 
Methods – This multicenter study looks study looks at all patients diagnosed with 7 
TS in the United Kingdom over a 24-year period. Fifteen centers in the British 8 
Congenital Arrhythmia Group network were contacted to partake in the study.  9 
Results - Six patients with Timothy syndrome were identified over a 24-year period 10 
(4 boys and 2 girls). Five out of six were confirmed to have a CACNA1C mutation 11 
(p.Gly406Arg) and the other patient was diagnosed clinically. Early presentation 12 
with heart block, due to QT prolongation was frequently seen. Four are still alive, 13 
two of these have a pacemaker and two have undergone defibrillator implantation. 14 
Five out of six patients have had a documented cardiac arrest with three occurring 15 
under general anesthesia. Two patients suffered a cardiac arrest while in hospital 16 
and resuscitation was unsuccessful, despite immediate access to a defibrillator. 17 
Surviving patients seem to have mild developmental delay and learning difficulties.  18 
Conclusion – Timothy syndrome is a rare disorder with a high attrition rate if 19 
undiagnosed. Perioperative cardiac arrests are common and not always amenable to 20 
resuscitation. Longer-term survival is possible, however patients invariably require 21 
pacemaker or defibrillator implantation.  22 
  23 
 7 
Introduction 1 
Timothy syndrome (TS) is an extremely rare multisystem disorder caused by a de 2 
novo mutation in the alternatively spliced exon 8A affecting CACNA1C, the gene 3 
encoding the CaV1.2 calcium channel (p.Gly406Arg).1-3 The CaV1.2 channel is critical 4 
for the plateau phase of the cardiac action potential, cellular excitability, excitation–5 
contraction coupling, and regulation of gene expression.4, 5 In TS the mutation 6 
causes impaired inactivation of open-state voltage-dependent L-type calcium 7 
channels, which results in a relatively sustained inward Ca2+ current.6  It is 8 
characterized by marked QT prolongation, syndactyly, immune deficiency, seizures, 9 
congenital heart defects, cognitive abnormalities, learning difficulties and 10 
intermittent hypoglycemia.2, 7 Timothy syndrome type 2 (TS2) is used to describe 11 
patients with the above phenotype but without syndactyly. Mutations in exon 8, 12 
rather than exon8A (p.Gly402Ser and p.Gly406Arg) have been described in TS2; 13 
differential expression of exon 8 / 8A in the heart and brain are thought to account 14 
for the different phenotypes.3  It is a remarkably genetically homogenous disorder, 15 
with most reported phenotypes accounted for by these two genotypes.3  16 
 17 
From the limited case reports available, both TS1 and TS2 usually present at a 18 
young age. The two most common modes of presentation are heart block as a result 19 
of QT prolongation and cardiac arrest.8 General anesthesia appears to be a 20 
particularly vulnerable time for these patients, with some undiagnosed patients 21 
presenting with a cardiac arrest during syndactyly surgery.9 Without treatment 22 
survival is unlikely due to the propensity for malignant arrhythmias. With improved 23 
 8 
understanding how antiarrhythmic medications affect the heart in TS, and better 1 
pacemaker / defibrillator therapies, survival into young adulthood is also possible.3  2 
In this study we looked at all patients who were diagnosed with TS1 and TS2 in the 3 
United Kingdom over a 24-year period, which represents the only multi-center 4 
published to date. 5 
  6 
 9 
Methods 1 
 2 
This is a multicenter study conducted on behalf of the British Congenital Arrhythmia 3 
group (BCAG), which is a network of all hospitals managing paediatric arrhythmias 4 
and inherited cardiac conditions in the United Kingdom. The network consists of 15 5 
centers, 12 of which perform paediatric cardiac surgery / interventions, and 3 of 6 
which are non-surgical. All centers have a paediatric cardiologist with a specialist 7 
interest in inherited cardiac conditions. The study was coordinated through Bristol 8 
Royal Hospital for Children. Research and ethics approval was obtained prior to 9 
commencing the study. Representatives for all centers were contacted to contribute 10 
cases. Any patients who were either born in, or currently reside in the United 11 
Kingdom were eligible for inclusion in the study.  12 
 13 
 14 
Patient Demographics  15 
Basic demographic details were collected from a combination of cases notes review, 16 
discussion with physicians, and discussions with TS patients’ families. In particular 17 
we were interested in the antenatal history, age at presentation, the presence of 18 
heart block, QTc at presentation, and medications. We collected data on 19 
interventions such as placement of pacemakers, ICDs, the timing of these 20 
interventions, and occurrence of appropriate / inappropriate shocks. Also, we 21 
looked at any non-arrhythmia related episodes of cardiovascular compromise.  22 
 23 
 24 
 10 
Genetics  1 
Most genetic testing inherited channelopathies are currently performed at Oxford 2 
Genetics Laboratories in the United Kingdom. We reviewed the database at this 3 
laboratory and there were no additional cases found other than the ones provided 4 
by the BCAG members. Other genetics laboratories were contacted to get specific 5 
details on mutations and to obtain illustrations. Given the rarity of this disorder and 6 
the high attrition rate, we thought that patients should be included if there was a 7 
strong index of suspicion, in the absence of genetic confirmation of the condition. 8 
Information was also requested on immediate family members, although genetic 9 
testing was not performed on any of them.   10 
 11 
 12 
Exon 8 of the CACNA1C gene (accession sequence NM_001167625.1) was amplified 13 
by PCR from genomic DNA (as supplied) using a readymade mastermix, KAPA2G 14 
Fast HS Readymix, supplied by Kappa Biosystems. Bidirectional fluorescent dideoxy 15 
sequencing was performed using Applied Biosystems Big Dye Terminator v3.1 kit 16 
followed by capillary electrophoresis on the Applied Biosystems 3730. Analysis 17 
involved manual interrogation at nucleotide position c.1216. Variant description is 18 
according to Human Genome Variation Society (HGVS) nomenclature. Internal 19 
quality control samples were run for each test, including negative (water blank), 20 
positive (DNA from the proband) and normal (previously assigned normal 21 
sequencing control). The test was undertaken using two non-overlapping primer 22 
sets so as to eliminate the possibility of allele drop out due to their being a 23 
polymorphism in the primer binding site.  24 
 11 
  1 
 12 
Results  1 
All 15 centers in the BCAG network were contacted and the response rate was 2 
100%. A total of six patients with TS were identified at five centers from January 3 
1992 to April 2016; ten centers confirmed that they didn’t have any cases. During 4 
this time period in the United Kingdom there were approximately 16 million live 5 
births, giving an approximate incidence of 1.5 in 108 births per year.10 In total there 6 
were 4 boys and 2 girls. Two of the patients were monozygous twins (both male). At 7 
the time of writing 4 out of 6 patients are still alive (table 1). Of the patients that are 8 
alive, two have pacemakers and two have had a defibrillator placed (table 2). A 9 
summary of the clinical course of all six patients is outlined below. There was no 10 
significant family history of sudden death in any of the patients. We were able to 11 
ascertain that 4 out of 5 parents of index cases were assessed clinically and did not 12 
demonstrate any clinical phenotypical features of TS. None of the parents of index 13 
cases underwent genetic testing.    14 
 15 
  16 
 13 
Patient # 1  1 
This patient was delivered at 28 weeks by emergency caesarian section (weight 980 2 
grams) for fetal bradycardia. The baby initially required ventilation for respiratory 3 
distress syndrome and remained intubated for four weeks after delivery. There was 4 
marked prolongation of the QT interval (QTc: 600 msec), which was causing 2:1 5 
heart block with hemodynamic instability. An attempt was made to slow the heart 6 
rate with intravenous propranolol, however propranolol administration caused 7 
further prolongation of the QT interval (Figure 1). A low dose of isoproterenol (0.01 8 
mcg/kg/min) was commenced which resulted in some improvement. Mexiletine (4 9 
mg/kg, Q8 hourly) was added at four weeks of age which resulted in further 10 
improvement, however intermittent 2:1 block was still present (Figure 2). Genetic 11 
testing confirmed the presence of a CACNA1C mutation. At eight weeks of age during 12 
induction of anesthesia for a Hickman line, the patient had an episode of ventricular 13 
fibrillation that required cardioversion. The isoproterenol infusion was continued at 14 
rates of 50 – 250 ng/kg/min until an epicardial pacemaker could be undertaken; 15 
this was performed at 12 weeks of age at a weight of 2.2 kg. Propranolol 1 mg / kg 16 
was also commenced, in addition to Mexiletine, once satisfactory pacing was 17 
achieved.   18 
 19 
The patient was discharged after a hospital stay of three months. At 12 months of 20 
age she was admitted to hospital with gastroenteritis and suffered another cardiac 21 
arrest. Cardiopulmonary resuscitation was performed immediately and an 22 
automated external defibrillator (AED) was attached; the rhythm was judged not to 23 
 14 
require cardioversion. The patient recovered after five minutes of resuscitation. 1 
There was mild hyperkalemia at the time of the cardiac arrest (6.7 mmol/L) and 2 
blood glucose was confirmed to be normal. At 15 months of age one of the epicardial 3 
leads became fractured. A transvenous pacemaker was placed without any 4 
complications. The patient’s current medications consist of mexiletine and 5 
propranolol. Regular Holter monitors have not demonstrated any arrhythmias. She 6 
is currently managed with a pacemaker and an AED, however consideration will be 7 
given to upgrade to an ICD when she is of sufficient size.   8 
9 
 15 
Patient #2  1 
 2 
Patient #2 was born at 30 weeks gestation (weight 1.5 kg) due to premature labor. 3 
The patient was noted to be in heart block on fetal echocardiograms. There was 4 
prolongation of the QT interval at birth (600 msec) with 2:1 heart block. The patient 5 
was noted to have syndactyly of the index, middle and ring fingers on both hands. 6 
Genetic testing confirmed the presence of a CACNA1C mutation. There was a patent 7 
ductus arteriosus and a ventricular septal defect which both closed spontaneously. 8 
The patient was maintained on atenolol initially and subsequently nadolol. A 9 
pacemaker was placed at two years of age. An episode of ventricular fibrillation 10 
occurred during induction of anesthesia that was treated with DC cardioversion. The 11 
patient was noted to have seizure activity on transfer to the ward afterwards, 12 
however made a good recovery and was discharged. During a respite hospice 13 
admission, he had another cardiac arrest that was cardioverted successfully by an 14 
AED. He was subsequently transferred to hospital and made a good recovery, 15 
although he did have some ongoing seizures. Unexpectedly, he had a sudden 16 
unprovoked cardiac arrest while still in hospital. Immediate cardiopulmonary 17 
resuscitation was commenced. His initial rhythm was pulseless electrical activity, 18 
which was followed soon afterwards by asystole. His pacemaker was functioning 19 
appropriately at the time and pacing at its lower limit. Blood glucose was checked 20 
around the time of cardiac arrest, which was normal.  21 
  22 
 16 
Patient #3 1 
 2 
This patient is likely one of the oldest patients alive with TS (24 years old). She was 3 
born at term with a weight of 3 kg. She had an out of hospital cardiac arrest at one 4 
year of age. She was successfully cardioverted from ventricular fibrillation and 5 
transferred to hospital. She had a QT interval of 600 msec, however it was not clear 6 
whether this was related to the cardiac arrest. There was no evidence of 7 
atrioventricular block. Other than a patent ductus arteriosus she had a structurally 8 
normal heart. She never had any seizures. She was treated with atenolol 1 mg / kg 9 
twice daily. Four years later she had another out-of-hospital cardiac arrest that 10 
resulted in a neurological injury. An epicardial defibrillator was placed at 5 years of 11 
age using pericardial patches and an endocardial pace-sense lead. She had an 12 
appropriate shock from this device at 8 years of age. Genetic testing confirmed the 13 
presence of a CACNA1C mutation. She had had multiple device changes and lead 14 
extractions. Currently she is living independently; she has mild learning difficulties 15 
and mild residual weakness as a result of her previous neurological injury.  16 
  17 
 17 
Patient #4 1 
A 13-month-old boy was admitted for bilateral syndactyly release.  He had soft 2 
systolic heart murmur, however it is not clear whether an echocardiogram was 3 
performed. There was syndactyly of the little and ring fingers. Anesthesia was 4 
induced and maintained with sevoflurane. One hour into the procedure, it was 5 
noticed that the patient was in ventricular bigeminy and T-wave alternans; all other 6 
parameters remained unchanged so the operation continued. One hour later, the 7 
patient had a cardiac arrest due to ventricular fibrillation, which was successfully 8 
cardioverted. Two further cardioversions were performed due to a reoccurrence of 9 
ventricular fibrillation. A narrow complex tachycardia followed, with good cardiac 10 
output. Subsequently a bradycardia ensued with no palpable pulse. Further 11 
attempts at resuscitation were unsuccessful and 75 minutes after the initial arrest, 12 
resuscitation was discontinued. The post mortem demonstrated a patent ductus 13 
arteriosus, a myocardial bridge over the right coronary artery, myocardial fibrosis 14 
and endocardial fibroelastosis.  Subsequent examination of the ECG strip confirmed 15 
the presence of a prolonged QT interval, which was unknown to the treating 16 
clinicians. Genetic testing was not performed on this patient  17 
  18 
 19 
  20 
 18 
Patient #5 1 
Twin I of monozygous twins, long QT syndrome was first suspected when transient 2 
2:1 atrioventricular block was noticed as a neonate. Serial ECGs showed persistent 3 
QTc prolongation of up to 554 ms and, despite the absence of symptoms, he was 4 
started on treatment with nadolol 1 mg/kg/day at the age of two years.  An episode 5 
of syncope at five years of age prompted implantation of a loop recorder.  On 6 
induction of anesthesia for this procedure he developed torsade de pointes, 7 
followed by sinus rhythm with T wave alternans (figure 5). A further episode of 8 
torsade de pointes was then documented, and an ICD was subsequently implanted 9 
for recurrent syncope despite adequate beta blockade. The ICD has delivered 10 
appropriate therapy on several occasions although there has been only one 11 
recurrence of arrhythmia (precipitated by a fire alarm at school) since the nadolol 12 
administration was changed to 0.5 mg/kg twice daily. Twin I’s QTc intervals have 13 
ranged from 522 to 554 ms. His other problems have included an inguinal hernia, 14 
congenital dysplasia of the hip, strabismus requiring glasses and otitis media with 15 
effusions, managed with grommets. His joints are hypermobile, and he wears splints 16 
to support his ankles and feet. He has global developmental delay, with delay in 17 
gross motor, fine motor skills, with a limited vocabulary, communicating primarily 18 
by signing.  At a recent assessment, he was on the 3rd centile for height (just below 19 
the lower limit of his parental range), and on the 25th centile for weight. At birth he 20 
was between the 50th and 75th centile for weight. Twin I does not have congenital 21 
heart disease. He does not have syndactyly. He has bilateral epicanthic folds but 22 
otherwise no facial dysmorphism.  23 
 19 
Subsequent molecular analysis demonstrated the pathogenic CACNA1C gene 1 
mutation c.1216G>A (pGly406Arg) in mosaic form in both twins. This mutation was 2 
absent, however, from both parents, suggesting that the mutation arose as a de novo 3 
event. Testing of DNA extracted from buccal smear samples confirmed that the 4 
mutation was present in both twins in mosaic form (Figure 4).  5 
 6 
  7 
 20 
Patient #6  1 
Twin II presented with cyanosis and was diagnosed with pulmonary atresia and 2 
ventricular septal defect. This was initially palliated with arterial shunts before 3 
repair with a Rastelli procedure at four years of age. His ECGs also showed a long 4 
QTc interval (range 493 to 555 ms), and he has been treated with nadolol since the 5 
age of two years. Other than transient 2:1 AV block he has not had overt arrhythmia. 6 
Other medical problems consisted of bilateral inguinal hernias and undescended 7 
testes requiring repair. Following one of the cardiac surgical procedures, he 8 
developed a Klebsiella urinary tract infection. He subsequently also developed 9 
Morexella endocarditis. Failure-to-thrive has recently been treated with growth 10 
hormone. At two years of age, he was found to be intolerant to lactose and soya. 11 
Following exclusion of these, his slow growth improved. Whilst twin II does not 12 
have strabismus, he has previously had abnormal eye movements. Investigation 13 
with electroencephalogram was normal. He weighed 1599 g at birth (10th centile). 14 
At a recent assessment, he was below the 3rd centile for height (3.85 STD below the 15 
mean) and weight just below the 3rd centile. He has hypermobile joints. Like his 16 
brother, twin II also has global development delay, particularly in the areas of 17 
speech and language, but also in fine and gross motor skills. He does not have 18 
syndactyly; he also has bilateral epicanthic folds but otherwise no facial 19 
dysmorphism. He has postural plagiocephaly. He currently has a single chamber 20 
pacemaker, however has not required placement of an ICD. 21 
  22 
 21 
Discussion  1 
This is the first multicenter study looking at outcomes for patients with TS. All 2 
patients in the series had the same mutation (p.Gly406Arg) affecting the CACNA1C 3 
gene. Early presentation is common and pacing / defibrillator placement is usually 4 
required. Patients are at high risk of ventricular arrhythmias, particularly during 5 
general anesthesia, indeed this was the initial presentation in one case. It is clearly a 6 
complex multisystem disorder, some of the facets of which are poorly understood: 7 
this is evident by the fact that 2 patients died in hospital despite good apparent 8 
resuscitation and appropriate cardioversion. Other patients have had successful 9 
cardioversion following cardiac arrest, demonstrating that defibrillator therapy can 10 
be life saving. Neurological impairments are frequent, most commonly seizures, as 11 
are mild learning difficulties. This study also demonstrates that with appropriate 12 
medical and device therapy, survival into adulthood is possible.  13 
 14 
As with other reports, this study demonstrates the genetic homogeneity of TS with 15 
all phenotypes resulting from the same mutation (p.Gly406Arg), exon 8A for TS1 16 
and exon 8 for TS2. It is a missense mutation in the pore-forming region of the 17 
CaV1.2 channel that is highly conserved across various species.3, 11 The other 18 
mutation described only in TS2 is a missense mutation, (p.Gly402Ser / exon 8)  and 19 
presents predominantly with cardiac involvement; we did not see this mutation in 20 
our study. The CaV1.2, transmembrane segment 6 of domain I (Figure 6), can be 21 
encoded by two mutually exclusive exons, 8 and 8A.3 The two phenotypes and the 22 
presence or absence of syndactyly are thought to be the result of differential 23 
 22 
expression of exons 8 / 8A, for instance exon 8 represents 80% of mRNAs in heart 1 
and brain. It is possible that some patients with TS2 may be undiagnosed due to the 2 
absence of syndactyly, and succumb early in life to malignant arrhythmias.    3 
 4 
Three patients in our study with TS1 demonstrated the abovementioned missense 5 
mutation (pGly406Arg) in exon 8A. The other two patients with TS2 (pGly406R 6 
mutation / exon 8) did not demonstrate as severe a phenotype due to a mosaic 7 
mutation. Mosaicism occurs as a result of genetically distinct populations in the 8 
somatic and germline tissues with heterogeneous expression, which may not follow 9 
Mendelian rules of inheritance.12, 13 With patient #5 and #6, the mutation was 10 
demonstrated to be absent from both parents thus occurring as a de novo, post-11 
zygotic event, after fusion of oocyte and spermatozoon but before cleavage of the 12 
zygote into monozygotic twin embryos. There are only two other published reports 13 
of mosaicism in TS, and these have described siblings with a more severe phenotype 14 
inherited from a phenotypically normal parent with a mosaic mutation.3, 12 The 15 
presence of mosaic mutations underlies the importance of testing tissues other than 16 
peripheral lymphocytes: for instance, buccal swabs in parents of index cases. This 17 
has important implications in counseling for future pregnancies.   18 
 19 
Mutations affecting the CaV1.2 channel have wide-reaching consequences. In 20 
addition to the electrical abnormalities, the presence of syndactyly, immune 21 
deficiency, seizures, congenital heart defects, cognitive abnormalities, learning 22 
difficulties and hypoglycemia underlie how different organ systems can be affected. 23 
 23 
With respect to the developing brain, L-type calcium channels are essential for 1 
linking electrical events to the activation of signaling pathways that regulate the 2 
development and function of neurons.14 Krey et al demonstrated that the impaired 3 
inactivation of the L-type calcium causes dendrite retraction when neurons are 4 
stimulated electrically.  The mechanism of action however is thought to be 5 
independent of calcium influx into the cell; rather, it may be due to a conformational 6 
change in the last transmembrane spanning region of the first repeat of CaV1.2, 7 
controlling Gem and RhoA signaling cascades.15 This provides an insight into how 8 
mutations in the CACNA1C gene might cause autistic traits and some of the other 9 
neurological abnormalities in this condition. One of our patients had documented 10 
recurrent hypoglycemia, although he was not hypoglycemic at the time of his 11 
cardiac arrest (patient #2). The mechanism of hypoglycemia likely relates to the 12 
effect of activation of L-type voltage-dependent calcium channels on the B-cells of 13 
the pancreas.16 It is possible that some of the unsuccessful resuscitations in this 14 
study may have been related to hypoglycemia. It was not known that the patient 15 
who died during syndactyly surgery had a prolonged QT interval until reviewed 16 
retrospectively. It is not usual practice for patients undergoing minor procedures to 17 
have a preoperative ECG. This underlies the importance for specialists dealing with 18 
syndactyly to be aware of this very rare condition, to obtain specialist input, and to 19 
have the procedure performed in a specialist centre.  20 
 21 
With respect to inactivation of calcium channels, it is thought that loss of voltage 22 
dependent inactivation is the predominant effect in TS.3, 4, 6 Recent studies however 23 
 24 
have suggested that Ca 2+ / Calmodulin dependent inactivation (CDI) also plays an 1 
important role: Dick et al have shown how the mutations p.Gly402Ser and 2 
p.Gly406Arg have different effects on CDI; also they showed a non-linear effect of TS 3 
gene expression on arrhythmia inducibility.17 This may explain why mosaic patients, 4 
such as the two seen in our study, have a comparatively milder phenotype. In terms 5 
of therapeutics it also means that we may not need to block all of the mutant TS 6 
channels to prevent arrhythmogenesis. There are 2 reported cases where verapamil 7 
has been used to treat TS. Jacobs report a reduction in the burden of ventricular 8 
tachycardia in a TS2 patient with the mutation Gly402Ser.7 In another patient with 9 
TS1 due to a mosaic p.Gly406Arg mutation, verapamil actually increased the 10 
arrhythmia burden.12 This illustrates how the same medication may produce 11 
different effects depending on the mutation and its level of expression. All of the 12 
surviving patients in our study mere managed in the longer term with β-blockers. As 13 
a newborn, patient #1 demonstrated lengthening of the QT interval with 14 
intravenous propranolol, thus perpetuating 2:1 block. This paradoxical QT 15 
prolongation with β-blocker administration has been seen in other studies and the 16 
cause remains unclear.18 Isoproterenol seemed to alleviate 2:1 block, however the 17 
improvement was intermittent and ultimately pacing was required. It does seem 18 
counterintuitive that most patients with TS are managed chronically with β-19 
blockers given their effect on the newborn QT interval.18 Mexiletine resulted in 20 
shortening of the QT interval in patient #1, which has been seen in other studies.18, 21 
19 Mexiletine works by inhibition of the late inward sodium channel current without 22 
having an effect on the inward calcium current.18 This current plays a role in the 23 
 25 
rate adaptation of ventricular repolarization. Inhibition of this current results in a 1 
blunted bradycardia dependent QT prolongation.18   2 
 3 
The presence of 2:1 block as a neonate usually indicates that early pacemaker 4 
placement will be required. The benefit of a pacemaker is two-fold; firstly, it 5 
improves cardiac output by preventing 2:1 block. Secondly, it prevents heart rate 6 
dependent variation of the QT interval.18 Whether it is performed endocardial or 7 
epicardial will depend on the patients weight and institutional practice. The benefit 8 
from pacing will usually outweigh any possible morbidity from the procedure once a 9 
baby has reached around 2.5 kg. Defibrillator placement at a young age will usually 10 
require a much higher burden of proof that there will be definite benefit. There is a 11 
high risk of device malfunction and inappropriate shocks at this age using an 12 
epicardial approach.20 It is also possible that defibrillation in some cases may be 13 
ineffective; two patients in our study died in hospital despite appropriate external 14 
defibrillation. Another patient (patient #1) had a cardiac arrest which was judged 15 
not to require cardioversion by an AED; this has also been reported in other 16 
patients.21 Current recommendations are that an ICD may be considered in high-risk 17 
patients such as those with TS without symptoms.22 Hypoglycemia is common in 18 
patients with TS and this may account for some cardiac arrests, however this was 19 
not definitely deemed to be a causative factor in any cases in our study. Bradycardia 20 
and asystole, despite presence of a pacemaker, was seen in two patients in our 21 
study. Two patients underwent defibrillator placement at 5 years of age, and both 22 
have received at least one appropriate shock. As patients get older the morbidity 23 
 26 
from defibrillators decreases, so implantation for primary prevention may be 1 
appropriate.   2 
 27 
Conclusions 1 
This is a multicenter study looking at all cases of TS patients in the United Kingdom 2 
over a 24-year period. If untreated, the mortality is high; however, with appropriate 3 
medical and device therapy, longer-term survival is possible. Due to the multiple 4 
systems affected by this disorder, not all deaths are related to tachyarrhythmias; 5 
hence, careful consideration must be given prior to implanting defibrillators in 6 
smaller patients. 7 
 8 
 9 
 28 
  Table 1. Baseline demographics  
 
 
Patient  Age# Gestation    Pregnancy  Delivery Gender 2:1 QTc * Syndactyly Seizures Other diagnosis  
      HB (msec) 
 
 
1    1 day  28/40 Normal  EmLSCS  F Yes 569 Yes Yes PDA 
 
2  1 day 30/40 Heart Block Normal  M Yes 600 Yes Yes PDA, VSD 
     
3   1 year  Term  Normal  Normal  F No NA Yes No PDA 
 
4   13 mths  Term  Normal   Normal  M No NA Yes No PDA, EFE, RCA bridge 
              
5      1 week  32/40 Twin   LSCS  M Yes 554 No No Inguinal Hernia  
 
6   1 day   32/40 Twin   LSCS  M Yes 555 No No Pulmonary atresia  
 
____________________________________________________________________________________________________________________________ 
 
#Age at presentation, *Rate corrected QT (QTc) interval at time of diagnosis (Bazett's correction), HB: heart 
block, LSCS: lower segment caesarian section, PDA: patent ductus arteriosus, VSD: ventricular septal defect, 
EFE: endocardial fibroelastosis, RCA: right coronary artery   
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  Table 2. Pacemaker and Defibrillator device information   
 
 
Patient  Alive  Current Current  Age at first      Appropriate  Cardiac Arrest    
  Device Age (years) Device ICD   shocks   
 
 
1    Yes PPM 1 yr, 7 mths PPM @ 8 wks  NA VF (related to anesthetic), Bradycardic arrest  
         
2  No NA - PPM @ 2 years  NA Asystolic arrest on cardiology ward    
     
3   Yes ICD 24 ICD @ 5 years  Yes  Multiple appropriate shocks  
 
4   No NA - None   NA torsade de pointes, not resuscitatable  
 
5       Yes ICD 7 ICD @ 5 years  Yes Multiple appropriate shocks  
 
6    Yes PPM 7 PPM @ 4 years  NA  None  
 
____________________________________________________________________________________________________________________ 
 
  
PPM:  permanent pacemaker, ICD: Internal Cardiac Defibrillator,  
 
 
  
 30 
  
 
 
 
 
Figure 1: Patient #1 at 2 days of age. There is marked prolongation of the QT 
and QTc intervals causing 2:1 block. Intravenous propranolol up to 0.3 mg/kg is 
administered and the QT interval increases, with no change to the 2:1 block.  
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Figure 2  
 
 
 
 
 
Figure 2: This ECG demonstrates a prolonged QT interval with 2:1 block causing a 
resultant bradycardia. 
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Figure 3  
 
 
 
 
Figure 3. Sanger sequence traces showing the G to A nucleotide substitution at position 
c.1216 in the proband. The G to A nucleotide substitution is not detected in the traces 
from the mother or fathers samples, which suggests a de novo occurrence.   
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Figure 4 
 
 
 
Figure 4: Electropherogram showing normal sequence of the end of exon 8 of the 
CACN1A gene from a control DNA sample (trace A) and DNA extracted from buccal 
epithelial cells from patient #5 (trace B). At base position 1216 in trace B there are two 
peaks, corresponding to the normal allele of the gene (G) and the mutant allele (A). In 
an heterozygous individual, the normal allele and mutant allele are both equally 
represented and the coloured peaks overlap. The marked difference in height of these 
peaks in trace B is consistent with the mutant allele being present at a lower level than 
the normal allele, indicating somatic mosaicism in buccal epithelial cells. 
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Figure 5
 
Figure 5 shows the prolonged QT interval in patient #5. On the right is the tracing from 
the loop recorder demonstrating torsade de pointes. An ICD was subsequently 
implanted. 
 
  
 35 
Figure 6 
 
Figure 6 shows the CaV1.2 calcium channel. The most commonly seen mutation 
(G406R) was the known mutation in 5 out of 6 patients in our study. It is missense 
mutation in the transmembrane segment S6 of domain 1.  
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